• 1. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 2. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 3. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 4. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 5. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Diterpenoids Aphidicolane and stemodane diterpenoids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Aphidicolane and stemodane diterpenoids
• Other Chemical Reagents

Introduction to Aphidicolin (CAS No. 38966-21-1)

Aphidicolin, a naturally occurring antibiotic and nucleoside analog, is chemically designated as 9-[(2-hydroxy-5-methyl-4H-pyrimidinyl)methyl]-6-(4-hydroxymethyl-2-methoxyphenyl)-9H-purin-2-one. This compound is identified by its unique chemical structure and has garnered significant attention in the field of chemotherapy and biomedical research due to its potent biological activities. With a CAS number of 38966-21-1, Aphidicolin is widely recognized for its role as an antiviral agent and its potential applications in the development of novel therapeutic strategies.

The discovery of Aphidicolin dates back to the mid-20th century when it was first isolated from the culture broth of *Streptomyces hygroscopicus*. Since then, extensive research has been conducted to elucidate its mechanism of action, chemical properties, and pharmacological effects. The compound belongs to the class of nucleoside analogs, which are synthetic or modified nucleoside derivatives that mimic the natural nucleosides involved in DNA and RNA synthesis. This structural similarity allows Aphidicolin to interfere with vital cellular processes, particularly those related to viral replication and cell division.

One of the most notable characteristics of Aphidicolin is its high affinity for inhibiting the enzyme DNA polymerase I. This enzyme is crucial for DNA replication in both prokaryotic and eukaryotic cells. By binding to DNA polymerase I, Aphidicolin effectively blocks the elongation of DNA strands, thereby preventing viral replication and cell proliferation. This mechanism has made it a valuable compound in the development of antiviral drugs, particularly against viruses that rely heavily on DNA polymerase for their life cycle.

Recent advancements in drug discovery and molecular biology have further highlighted the potential of Aphidicolin in addressing various therapeutic challenges. Studies have demonstrated its efficacy against a range of viruses, including herpesviruses and papillomaviruses. Moreover, research has explored its applications in treating certain types of cancer by inhibiting tumor cell proliferation. The compound's ability to selectively target rapidly dividing cells makes it a promising candidate for chemotherapy regimens.

In addition to its antiviral and anticancer properties, Aphidicolin has also been investigated for its potential role in regulating cellular processes such as apoptosis and autophagy. These processes are critical for maintaining cellular homeostasis and have been implicated in various diseases, including neurodegenerative disorders. Emerging research suggests that Aphidicolin may modulate these pathways, offering new insights into potential therapeutic interventions.

The chemical structure of Aphidicolin plays a pivotal role in determining its biological activity. Its unique arrangement of hydroxymethyl and methoxy groups contributes to its ability to interact with biological targets such as DNA polymerase I and other enzymes involved in nucleic acid metabolism. This structural complexity has also been leveraged in designing derivatives with enhanced pharmacological properties. For instance, modifications to the purine ring or the pyrimidine moiety have led to compounds with improved solubility, bioavailability, and reduced toxicity.

From a synthetic chemistry perspective, Aphidicolin serves as an excellent scaffold for developing novel therapeutic agents. The availability of synthetic routes allows researchers to modify various functional groups while retaining the core structure responsible for biological activity. This flexibility has enabled the creation of a library of derivatives with tailored properties, facilitating high-throughput screening for new drug candidates.

The pharmacokinetic profile of Aphidicolin is another critical aspect that influences its clinical applicability. Studies have shown that it exhibits moderate oral bioavailability but may require parenteral administration for optimal therapeutic effects. Understanding these pharmacokinetic parameters is essential for designing effective dosing regimens and minimizing potential side effects.

In conclusion, Aphidicolin (CAS No. 38966-21-1) is a multifaceted compound with significant implications in antiviral therapy, cancer research, and broader biomedical applications. Its unique chemical structure, potent biological activities, and well-documented mechanisms make it a cornerstone in the development of novel therapeutic strategies. As research continues to uncover new aspects of its pharmacology and potential applications, Aphidicolin remains a subject of intense interest among scientists and clinicians alike.

• 56663-60-6(grayanotoxane-3,5,6,7,10,14,16-heptol)
• 122871-21-0((10S)-3c,8c,12c,14c,17c-Pentahydroxy-10r,13c-dimethyl-17t-((Xi)-1-hydroxy-aethyl)-(5tH,9tH)-hexadecahydro-1H-cyclopenta[a]phenanthren)
• 54781-61-2((3beta,6beta)-grayanotoxane-3,5,6,10,16-pentol)
• 53452-33-8(2beta,14beta,15alpha,16alpha,17-pentahydroxy-ent-kaurane)
• 72534-12-4((1beta, 3beta, 5alpha, 6beta)-Cholestane-1, 3, 5, 6-tetrol)
• 6215-40-3(N-(2,1,3-benzothiadiazol-4-yl)-2,2-diphenylacetamide)
• 3615-89-2((3alpha,5beta,20S)-pregnane-3,17,20,21-tetrol)
• 102988-63-6(27-nor-5alpha-cholestane-3beta,4beta,5,6alpha,7beta,8,14,15alpha,24alpha-nonaol)
• 37720-87-9((14R)-Grayanotoxane-2α,3β,5,6β,10,14,16-heptol)
• 59236-84-9((6beta,14S)-grayanotoxane-5,6,10,14,16-pentol)